-
Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-22 Dorene M. Rentz, Paul S. Aisen, Alireza Atri, Janice Hitchcock, Michael Irizarry, Jaren Landen, Brandy R. Matthews, David S. Miller, Simin Mahinrad, Salvatore Napoli, Hamid R. Okhravi, Ronald C. Petersen, Eric R. Siemers, Christopher J. Weber, David C. Weisman, Maria C. Carrillo
The emergence of the United States Food and Drug Administration (FDA)-approved amyloid-targeting therapies for Alzheimer's disease challenges clinicians and healthcare providers with a transformative landscape. Effectively communicating the risks, benefits, burdens, costs, and available support associated with these novel disease-modifying treatments to patients, families, and other healthcare providers
-
The plasma miRNAome in ADNI: Signatures to aid the detection of at-risk individuals Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-18 Dennis M. Krüger, Tonatiuh Pena-Centeno, Shiwei Liu, Tamina Park, Lalit Kaurani, Ranjit Pradhan, Yen-Ning Huang, Shannon L. Risacher, Susanne Burkhardt, Anna-Lena Schütz, Yang Wan, Leslie M. Shaw, Alexander S. Brodsky, Anita L. DeStefano, Honghuang Lin, Robert Schroeder, Andre Krunic, Nina Hempel, Farahnaz Sananbenesi, Jan Krzysztof Blusztajn, Andrew J. Saykin, Ivana Delalle, Kwangsik Nho, Andre Fischer
MicroRNAs are short non-coding RNAs that control proteostasis at the systems level and are emerging as potential prognostic and diagnostic biomarkers for Alzheimer's disease (AD).
-
Plasma miRNAs across the Alzheimer's disease continuum: Relationship to central biomarkers Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-18 Shiwei Liu, Tamina Park, Dennis M. Krüger, Tonatiuh Pena-Centeno, Susanne Burkhardt, Anna-Lena Schutz, Yen-Ning Huang, Thea Rosewood, Soumilee Chaudhuri, MinYoung Cho, Shannon L. Risacher, Yang Wan, Leslie M. Shaw, Farahnaz Sananbenesi, Alexander S. Brodsky, Honghuang Lin, Andre Krunic, Jan Krzysztof Blusztajn, Andrew J. Saykin, Ivana Delalle, Andre Fischer, Kwangsik Nho
MicroRNAs (miRNAs) play important roles in gene expression regulation and Alzheimer's disease (AD) pathogenesis.
-
Pilot implementation of the revised criteria for staging of Alzheimer's disease by the Alzheimer's Association Workgroup in a tertiary memory clinic Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-17 Jiaying Lu, Jing Wang, Jie Wu, Huiwei Zhang, Xiaoxi Ma, Yuhua Zhu, Jie Wang, Yunhao Yang, Zhenxu Xiao, Ming Li, Xiaowen Zhou, Zizhao Ju, Qian Xu, Jingjie Ge, Ding Ding, Tzu-Chen Yen, Chuantao Zuo, Yihui Guan, Qianhua Zhao
We aimed to evaluate the feasibility of the 2024 Alzheimer's Association Workgroup's integrated clinical-biological staging scheme in outpatient settings within a tertiary memory clinic.
-
Integrating amyloid imaging and genetics for early risk stratification of Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-17 Bing He, Ruiming Wu, Neel Sangani, Pradeep Varathan Pugalenthi, Alice Patania, Shannon L. Risacher, Kwangsik Nho, Liana G. Apostolova, Li Shen, Andrew J. Saykin, Jingwen Yan
Alzheimer's disease (AD) initiates years prior to symptoms, underscoring the importance of early detection. While amyloid accumulation starts early, individuals with substantial amyloid burden may remain cognitively normal, implying that amyloid alone is not sufficient for early risk assessment.
-
Inflammatory protein associations with brain MRI measures: Framingham Offspring Cohort Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-16 Jiachen Chen, Ahmed A. Y. Ragab, Margaret F. Doyle, Michael L. Alosco, Yuan Fang, Jesse Mez, Claudia L. Satizabal, Wei Qiao Qiu, Joanne M. Murabito, Kathryn L. Lunetta
Brain magnetic resonance imaging (MRI) and inflammatory biomarkers are crucial for investigating preclinical neurocognitive disorders. Current investigations focus on a few inflammatory markers. The study aims to investigate the associations between inflammatory biomarkers and MRI measures and to examine sex differences among the associations in the Framingham Heart Study.
-
Morphometry of medial temporal lobe subregions using high-resolution T2-weighted MRI in ADNI3: Why, how, and what's next? Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-16 Paul A. Yushkevich, Ranjit Ittyerah, Yue Li, Amanda E. Denning, Niyousha Sadeghpour, Sydney Lim, Emily McGrew, Long Xie, Robin DeFlores, Christopher A. Brown, Laura E. M. Wisse, David A. Wolk, Sandhitsu R. Das
This paper for the 20th anniversary of the Alzheimer's Disease Neuroimaging Initiative (ADNI) provides an overview of magnetic resonance imaging (MRI) of medial temporal lobe (MTL) subregions in ADNI using a dedicated high-resolution T2-weighted sequence. A review of the work that supported the inclusion of this imaging modality into ADNI Phase 3 is followed by a brief description of the ADNI MTL imaging
-
Predicting CDR status over 36 months with a recall-based digital cognitive biomarker Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-11 Davide Bruno, Ainara Jauregi-Zinkunegi, Jason R. Bock
Word-list recall tests are routinely used for cognitive assessment, and process scoring may improve their accuracy. We examined whether Alzheimer's Disease Assessment Scale–Cognitive subscale (ADAS-Cog) derived, process-based digital cognitive biomarkers (DCBs) at baseline predicted Clinical Dementia Rating (CDR) longitudinally and compared them to standard metrics.
-
Associations between misfolded alpha-synuclein aggregates and Alzheimer's disease pathology in vivo Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-11 Alexa Pichet Binette, Angela Mammana, Laura Wisse, Marcello Rossi, Olof Strandberg, Ruben Smith, Niklas Mattsson-Carlgren, Shorena Janelidze, Sebastian Palmqvist, , Alice Ticca, Erik Stomrud, Piero Parchi, Oskar Hansson
We examined the relations of misfolded alpha synuclein (α-synuclein) with Alzheimer's disease (AD) biomarkers in two large independent cohorts.
-
Overview of ADNI MRI Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-11 Clifford R. Jack, Arvin Arani, Bret J. Borowski, Dave M. Cash, Karen Crawford, Sandhitsu R. Das, Charles DeCarli, Evan Fletcher, Nick C. Fox, Jeffrey L. Gunter, Ranjit Ittyerah, Danielle J. Harvey, Neda Jahanshad, Pauline Maillard, Ian B. Malone, Talia M. Nir, Robert I. Reid, Denise A. Reyes, Christopher G. Schwarz, Matthew L. Senjem, David L. Thomas, Paul M. Thompson, Duygu Tosun, Paul A. Yushkevich
The magnetic resonance imaging (MRI) Core has been operating since Alzheimer's Disease Neuroimaging Initiative's (ADNI) inception, providing 20 years of data including reliable, multi-platform standardized protocols, carefully curated image data, and quantitative measures provided by expert investigators. The overarching purposes of the MRI Core include: (1) optimizing and standardizing MRI acquisition
-
Factors associated with cognitive reserve according to education level Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-10 Yeshin Kim, Yaakov Stern, Sang Won Seo, Duk L. Na, Jae-Won Jang, Hyemin Jang
We investigated distinctive factors associated with cognitive reserve (CR) based on education level.
-
Hypertension and cerebral blood flow in the development of Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-10 Dario Bachmann, Antje Saake, Sandro Studer, Andreas Buchmann, Katrin Rauen, Esmeralda Gruber, Lars Michels, Roger M. Nitsch, Christoph Hock, Anton Gietl, Valerie Treyer
We investigated the interactive associations between amyloid and hypertension on the entorhinal cortex (EC) tau and atrophy and the role of cerebral blood flow (CBF) as a shared mechanism by which amyloid and hypertension contribute to EC tau and regional white matter hyperintensities (WMHs).
-
Amygdala atrophies in specific subnuclei in preclinical Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-10 Yasmine Salman, Thomas Gérard, Lara Huyghe, Lise Colmant, Lisa Quenon, Vincent Malotaux, Adrian Ivanoiu, Renaud Lhommel, Laurence Dricot, Bernard J. Hanseeuw
Magnetic resonance imaging (MRI) segmentation algorithms make it possible to study detailed medial temporal lobe (MTL) substructures as hippocampal subfields and amygdala subnuclei, offering opportunities to develop biomarkers for preclinical Alzheimer's disease (AD).
-
Combining cerebrospinal fluid and PI‐2620 tau‐PET for biomarker‐based stratification of Alzheimer's disease and 4R‐tauopathies Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-12 Roxane Dilcher, Stephan Wall, Mattes Groß, Sabrina Katzdobler, Olivia Wagemann, Carla Palleis, Endy Weidinger, Urban Fietzek, Alexander Bernhardt, Carolin Kurz, Christian Ferschmann, Maximilian Scheifele, Mirlind Zaganjori, Johannes Gnörich, Katharina Bürger, Daniel Janowitz, Boris‐Stephan Rauchmann, Sophia Stöcklein, Peter Bartenstein, Victor Villemagne, John Seibyl, Osama Sabri, Henryk Barthel, Robert
INTRODUCTIONRecent advances in biomarker research have improved the diagnosis and monitoring of Alzheimer's disease (AD), but in vivo biomarker‐based workflows to assess 4R‐tauopathy (4RT) patients are currently missing. We suggest a novel biomarker‐based algorithm to characterize AD and 4RTs.METHODSWe cross‐sectionally assessed combinations of cerebrospinal fluid measures (CSF p‐tau181 and t‐tau)
-
Detection of sex‐specific glutamate changes in subregions of hippocampus in an early‐stage Alzheimer's disease mouse model using GluCEST MRI Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-12 Narayan Datt Soni, Anshuman Swain, Halvor Juul, Quy Cao, Mohammad Haris, David A. Wolk, Virginia M.‐Y. Lee, John A. Detre, Ravi Prakash Reddy Nanga, Ravinder Reddy
INTRODUCTIONRegional glucose hypometabolism resulting in glutamate loss has been shown as one of the characteristics of Alzheimer's disease (AD). Because the impact of AD varies between the sexes, we utilized glutamate‐weighted chemical exchange saturation transfer (GluCEST) magnetic resonance imaging (MRI) for high‐resolution spatial mapping of cerebral glutamate and investigated subregional changes
-
Cognitive resilience to Alzheimer's disease characterized by cell‐type abundance Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-12 Nicholas O'Neill, Thor D. Stein, Oluwatosin A. Olayinka, Jenny A. Empawi, Junming Hu, Tong Tong, Xiaoling Zhang, Lindsay A. Farrer
INTRODUCTIONThe molecular basis of cognitive resilience (CR) among pathologically confirmed Alzheimer's disease (AD) cases is not well understood.METHODSAbundance of 13 cell types and neuronal subtypes in brain bulk RNA‐seq data from the anterior caudate, dorsolateral prefrontal cortex (DLPFC), and posterior cingulate cortex (PCC) obtained from 434 AD cases, 318 cognitively resilient AD cases, and
-
Genetic spectrum features and diagnostic accuracy of four plasma biomarkers in 248 Chinese patients with frontotemporal dementia Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-10 Tianyan Xu, Ling Weng, Cong Zhang, Xuewen Xiao, Qijie Yang, Yuan Zhu, Yafang Zhou, Xinxin Liao, Shilin Luo, Junling Wang, Beisha Tang, Bin Jiao, Lu Shen
INTRODUCTIONFrontotemporal dementia (FTD) is characterized by phenotypic and genetic heterogeneities. However, reports on the large Chinese FTD cohort are lacking.METHODSTwo hundred forty‐eight patients with FTD were enrolled. All patients and 2010 healthy controls underwent next generation sequencing. Plasma samples were analyzed for glial fibrillary acidic protein (GFAP), α‐synuclein (α‐syn), neurofilament
-
Gender differences in the association between education and late‐life cognitive function in the LifeAfter90 Study: A multiethnic cohort of the oldest–old Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-10 Jennifer O. Lam, Rachel A. Whitmer, Maria M. Corrada, Claudia H. Kawas, Katherine E. Vieira, Charles P. Quesenberry, Paola Gilsanz
INTRODUCTIONFew studies have examined the relationship between education and cognition among the oldest–old.METHODSCognitive assessments were conducted biannually for 803 participants (62.6% women) of LifeAfter90, a longitudinal study of individuals ≥ 90 years old. Gender differences in associations between education (< high school, high school, some college, and ≥ college) and cognition (verbal episodic
-
Better cardiovascular health is associated with slowed clinical progression in autosomal dominant frontotemporal lobar degeneration variant carriers Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-06 Anna M. VandeBunte, Hyunwoo Lee, Emily W. Paolillo, Ging-Yuek Robin Hsiung, Adam M. Staffaroni, Rowan Saloner, Carmela Tartaglia, Kristine Yaffe, David S. Knopman, Eliana Marisa Ramos, Katya Rascovsky, Andrea C. Bozoki, Bonnie Wong, Kimiko Domoto-Reilly, Allison Snyder, Peter Pressman, Mario F. Mendez, Irene Litvan, Julie A. Fields, Douglas R. Galasko, Ryan Darby, Joseph C. Masdeu, Maria Belen Pasqual
Cardiovascular health is important for brain aging, yet its role in the clinical manifestation of autosomal dominant or atypical forms of dementia has not been fully elucidated. We examined relationships between Life's Simple 7 (LS7) and clinical trajectories in individuals with autosomal dominant frontotemporal lobar degeneration (FTLD).
-
Digital cognitive assessments as low-burden markers for predicting future cognitive decline and tau accumulation across the Alzheimer's spectrum Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-06 Casey R. Vanderlip, Craig E. L. Stark
Digital cognitive assessments, particularly those that can be done at home, present as low-burden biomarkers for participants and patients alike, but their effectiveness in the diagnosis of Alzheimer's disease (AD) or predicting its trajectory is still unclear. Here, we assessed what utility or added value these digital cognitive assessments provide for identifying those at high risk of cognitive decline
-
Storyteller in ADNI4: Application of an early Alzheimer's disease screening tool using brief, remote, and speech-based testing Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-05 Caroline Skirrow, Udeepa Meepegama, Jack Weston, Melanie J. Miller, Rachel L. Nosheny, Bruce Albala, Michael W. Weiner, Emil Fristed
Speech-based testing shows promise for sensitive and scalable objective screening for Alzheimer's disease (AD), but research to date offers limited evidence of generalizability.
-
Personalizing progressive changes to brain structure in Alzheimer's disease using normative modeling Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-05 Serena Verdi, Saige Rutherford, Charlotte Fraza, Duygu Tosun, Andre Altmann, Lars Lau Raket, Jonathan M. Schott, Andre F. Marquand, James H. Cole
Neuroanatomical normative modeling captures individual variability in Alzheimer's disease (AD). Here we used normative modeling to track individuals’ disease progression in people with mild cognitive impairment (MCI) and patients with AD.
-
Pathways to personalized medicine—Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-06 Steven E. Arnold, Bradley T. Hyman, Rebecca A. Betensky, Hiroko H. Dodge
Biological and clinical heterogeneity is a major challenge in research for developing new treatments for Alzheimer's disease (AD). AD may be defined by its amyloid beta and tau pathologies, but we recognize that mixed pathologies are common, and that diverse genetics, central nervous system (CNS) and systemic pathophysiological processes, and environmental/experiential factors contribute to AD's diverse
-
Cognitive modeling of the Mnemonic Similarity Task as a digital biomarker for Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-06 Casey R. Vanderlip, Michael D. Lee, Craig E. L. Stark
BACKGROUNDThe Mnemonic Similarity Task (MST) is a popular memory task designed to assess hippocampal integrity. We assessed whether analyzing MST performance using a multinomial processing tree (MPT) cognitive model could detect individuals with elevated Alzheimer's disease (AD) biomarker status prior to cognitive decline.METHODWe analyzed MST data from >200 individuals (young, cognitively healthy
-
Alzheimer's Association launches new journal on the impacts of behavioral, social, and economic factors on health and dementia care in aging Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-06
The Alzheimer's Association® announces the launch of its newest open-access, peer-reviewed journal, Alzheimer's & Dementia®: Behavior & Socioeconomics of Aging (A&D: BSEA), the fourth in the Alzheimer's & Dementia family of journals®. The new journal examines how economic, social, and behavioral factors impact and inform health policy, interventions, and strategies of dementia care and health outcomes
-
The role of the Alzheimer's Association in the genesis of Alzheimer's Disease Neuroimaging Initiative Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-06 Maria C. Carrillo, Simin Mahinrad, Heather M. Snyder, Zaven Khachaturian
Here we highlight the Alzheimer's Association's role since its inception, as a strategic collaborator with National Institutes of Health–National Institute on Aging in the development of the modern era of the Alzheimer's Movement and in making Alzheimer's disease (AD) a national priority in the United States by developing several initiatives to advance knowledge about the cause, diagnosis, and treatment
-
Subjective cognitive decline and cognitive change among diverse middle‐aged and older Hispanic/Latino adults: Results from the Study of Latinos–Investigation of Neurocognitive Aging (SOL‐INCA) Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-05 Freddie Márquez, Wassim Tarraf, Sayaka Kuwayama, Deisha F. Valencia, Ariana M. Stickel, Alejandra Morlett‐Paredes, Lourdes R. Guerrero, Krista M. Perreira, Sylvia Wassertheil‐Smoller, Sara Gonzalez, Christian R. Salazar, Martha L. Daviglus, Linda C. Gallo, Hector M. González
INTRODUCTIONThe potential utility of subjective cognitive decline (SCD) as an early risk marker of Alzheimer's disease and related dementias is under consideration. We examined associations between SCD and cognitive change among middle‐aged and older Hispanic/Latino adults living in the United States.METHODSThe short‐form Everyday Cognition Scale (ECog‐12) was assessed to generate global, executive
-
Circulating apoE4 protein levels from dried blood spots predict cognitive function in a large population‐based survey setting Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-05 Yacila I. Deza‐Lougovski, Luzia M. Weiss, Hannah M. Horton, Aijing Sun, Nis Borbye‐Lorenzen, Kristin Skogstrand, Solveig Holmgaard, Karen Andersen‐Ranberg, Vania Panes Lundmark, Axel Börsch‐Supan, Martina Börsch‐Supan, Anna Rieckmann
INTRODUCTIONThe apolipoprotein E (APOE) ε4 allele carries risk for cognitive impairment, but whether the level of circulating apoE4 protein in carriers affects cognition is unclear, as is how health and lifestyle impact circulating apoE4 levels.METHODSWe assayed apoE4 protein levels in dried blood spots of 12,532 adults aged 50+. Regression analyses tested the likelihood of cognitive impairment between
-
Missense and loss‐of‐function variants at GWAS loci in familial Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-05 Tamil Iniyan Gunasekaran, Dolly Reyes‐Dumeyer, Kelley M. Faber, Alison Goate, Brad Boeve, Carlos Cruchaga, Margaret Pericak‐Vance, Jonathan L. Haines, Roger Rosenberg, Debby Tsuang, Diones Rivera Mejia, Martin Medrano, Rafael A. Lantigua, Robert A. Sweet, David A. Bennett, Robert S. Wilson, Camille Alba, Clifton Dalgard, Tatiana Foroud, Badri N. Vardarajan, Richard Mayeux
BACKGROUNDFew rare variants have been identified in genetic loci from genome‐wide association studies (GWAS) of Alzheimer's disease (AD), limiting understanding of mechanisms, risk assessment, and genetic counseling.METHODSUsing genome sequencing data from 197 families in the National Institute on Aging Alzheimer's Disease Family Based Study and 214 Caribbean Hispanic families, we searched for rare
-
Loneliness, cerebrovascular and Alzheimer's disease pathology, and cognition Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-05 Patrick Lao, Christina B. Young, Chima Ezeh, Bayardo Lacayo, Dominika Seblova, Ryan M. Andrews, Laura Gibbons, A. Zarina Kraal, Indira Turney, Kacie D. Deters, Vonetta Dotson, Jennifer J. Manly, Lisa L. Barnes, Laura B. Zahodne
INTRODUCTIONLoneliness has a rising public health impact, but research involving neuropathology and representative cohorts has been limited.METHODSInverse odds of selection weights were generalized from the autopsy sample of Rush Alzheimer's Disease Center cohorts (N = 680; 89 ± 9 years old; 25% dementia) to the US‐representative Health and Retirement Study (N = 8469; 76 ± 7 years old; 5% dementia)
-
An 18‐month multimodal intervention trial for preventing dementia: J‐MINT PRIME Tamba Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-04 Yutaro Oki, Tohmi Osaki, Ryoko Kumagai, Shunsuke Murata, Haruhi Encho, Rei Ono, Hisafumi Yasuda, Hisatomo Kowa
BACKGROUNDThe number of people with dementia is increasing in Japan, and establishing evidence for preventing dementia is necessary.METHODSThis study was a randomized controlled trial in cognitively normal community‐dwelling older adults aged 65 to 85 with diabetes and/or hypertension. Participants were randomly assigned in a 1:1 ratio. The intervention group underwent 90 min of group‐based weekly
-
White matter hyperintensity on MRI and plasma Aβ42/40 ratio additively increase the risk of cognitive impairment in hypertensive adults Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-04 Adam de Havenon, Rebecca F. Gottesman, Jeff D. Willamson, Natalia Rost, Richa Sharma, Vivian Li, Lauren Littig, Eric Stulberg, Guido J. Falcone, Shyam Prabhakaran, Andrea L. C. Schneider, Kevin N. Sheth, Nicholas M. Pajewski, Adam M. Brickman
INTRODUCTIONDementia often involves comorbid Alzheimer's and vascular pathology, but their combined impact warrants additional study.METHODSWe analyzed the Systolic Blood Pressure Intervention Trial and categorized white matter hyperintensity (WMH) volume into highest versus lowest/mid tertile and the amyloid beta (Aβ)42/40 ratio into lowest versus mid/highest ratio tertile. Using these binary variables
-
Utility of cerebrovascular imaging biomarkers to detect cerebral amyloidosis Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-01 Matthew D. Howe, Megan R. Caruso, Masood Manoochehri, Zachary J. Kunicki, Sheina Emrani, James L. Rudolph, Edward D. Huey, Stephen P. Salloway, Hwamee Oh
The relationship between cerebrovascular disease (CVD) and amyloid beta (Aβ) in Alzheimer's disease (AD) is understudied. We hypothesized that magnetic resonance imaging (MRI)–based CVD biomarkers—including cerebral microbleeds (CMBs), lacunar infarction, and white matter hyperintensities (WMHs)—would correlate with Aβ positivity on positron emission tomography (Aβ-PET).
-
Brain network dynamics in patients with single- and multiple-domain amnestic mild cognitive impairment Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-01 Tiantian Liu, Mingjun Wang, Jian Zhang, Chuyang Ye, Shintaro Funahashi, Jianghong Liu, Li Wang, Tianyi Yan
Brain network dynamics have been extensively explored in patients with amnestic mild cognitive impairment (aMCI); however, differences in single- and multiple-domain aMCI (SD-aMCI and MD-aMCI) remain unclear.
-
The ADNI4 Digital Study: A novel approach to recruitment, screening, and assessment of participants for AD clinical research Alzheimers Dement. (IF 13.0) Pub Date : 2024-09-01 Melanie J. Miller, Adam Diaz, Catherine Conti, Bruce Albala, Derek Flenniken, Juliet Fockler, Winnie Kwang, Diana Truran Sacrey, Miriam T. Ashford, Caroline Skirrow, Jack Weston, Emil Fristed, Sarah Tomaszewski Farias, Magda Korecka, Yang Wan, Paul S. Aisen, Laurel Beckett, Danielle Harvey, Edward B. Lee, Ronald C. Petersen, Leslie M. Shaw, Ozioma C. Okonkwo, Monica Rivera Mindt, Michael W. Weiner
We evaluated preliminary feasibility of a digital, culturally-informed approach to recruit and screen participants for the Alzheimer's Disease Neuroimaging Initiative (ADNI4).
-
Synergistic associations of CD33 variants and hypertension with brain and cognitive aging among dementia-free older adults: A population-based study Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-30 Min Zhu, Xunyao Tian, Xiaodong Han, Yixun Ma, Wenxin Fa, Nan Wang, Rui Liu, Yi Dong, Yifei Ren, Cuicui Liu, Na Tian, Heng Zhang, Lin Song, Shi Tang, Lin Cong, Yongxiang Wang, Tingting Hou, Chengxuan Qiu, Yifeng Du
CD33 rs3865444 and hypertension (HTN) are related to cognitive impairment, individually. However, little is known about their combined effects on cognitive function in older adults.
-
Ischemic stroke associated with amyloid‐related imaging abnormalities in a patient treated with lecanemab Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-31 Alec W. Gibson, Holly Elser, Michela Rosso, Eli J. Cornblath, Yombe Fonkeu, Sashank Prasad, Aaron Rothstein, Ilya M. Nasrallah, David A. Wolk, Michael H. Guo
INTRODUCTIONAnti‐amyloid antibody therapies such as lecanemab are increasingly being used to treat Alzheimer's disease (AD). These therapies are associated with a high rate of amyloid‐related imaging abnormalities (ARIA).METHODSWe review the case history of a patient who developed ARIA associated with lecanemab treatment.RESULTSIn addition to microhemorrhages and cerebral edema that are recognized
-
Bridging the gap: Multi‐omics profiling of brain tissue in Alzheimer's disease and older controls in multi‐ethnic populations Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-31 Joseph S. Reddy, Laura Heath, Abby Vander Linden, Mariet Allen, Katia de Paiva Lopes, Fatemeh Seifar, Erming Wang, Yiyi Ma, William L. Poehlman, Zachary S. Quicksall, Alexi Runnels, Yanling Wang, Duc M. Duong, Luming Yin, Kaiming Xu, Erica S. Modeste, Anantharaman Shantaraman, Eric B. Dammer, Lingyan Ping, Stephanie R. Oatman, Jo Scanlan, Charlotte Ho, Minerva M. Carrasquillo, Merve Atik, Geovanna
INTRODUCTIONMulti‐omics studies in Alzheimer's disease (AD) revealed many potential disease pathways and therapeutic targets. Despite their promise of precision medicine, these studies lacked Black Americans (BA) and Latin Americans (LA), who are disproportionately affected by AD.METHODSTo bridge this gap, Accelerating Medicines Partnership in Alzheimer's Disease (AMP‐AD) expanded brain multi‐omics
-
Blood-based multivariate methylation risk score for cognitive impairment and dementia Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-28 Jarno Koetsier, Rachel Cavill, Rick Reijnders, Joshua Harvey, Jan Homann, Morteza Kouhsar, Kay Deckers, Sebastian Köhler, Lars M. T. Eijssen, Daniel L. A. van den Hove, Ilja Demuth, Sandra Düzel, , Rebecca G. Smith, Adam R. Smith, Joe Burrage, Emma M. Walker, Gemma Shireby, Eilis Hannon, Emma Dempster, Tim Frayling, Jonathan Mill, Valerija Dobricic, Peter Johannsen, Michael Wittig, Andre Franke, Rik
The established link between DNA methylation and pathophysiology of dementia, along with its potential role as a molecular mediator of lifestyle and environmental influences, positions blood-derived DNA methylation as a promising tool for early dementia risk detection.
-
Cellular prion protein acts as mediator of amyloid beta uptake by caveolin‐1 causing cellular dysfunctions in vitro and in vivo Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-30 Angela da Silva Correia, Matthias Schmitz, Anna‐Lisa Fischer, Susana da Silva Correia, Franco L. Simonetti, Gesine Saher, Roberto Goya‐Maldonado, Amandeep Singh Arora, Andre Fischer, Tiago F. Outeiro, Inga Zerr
INTRODUCTIONCellular prion protein (PrPC) was implicated in amyloid beta (Aβ)‐induced toxicity in Alzheimer's disease (AD), but the precise molecular mechanisms involved in this process are unclear.METHODSDouble transgenic mice were generated by crossing Prnp knockout (KO) with 5xFAD mice, and light‐sheet microscopy was used for whole brain tissue analyses. PrPC‐overexpressing cells were developed
-
Community recruitment of underrepresented populations to the AHEAD 3‐45 preclinical AD trial using novel partnerships with nursing and community‐based organizations: Lessons and outcomes Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-30 Christian R. Salazar, Melanie Tallakson, Maria G. Corona, Edwin Duran, Eunji Russ, Dan Hoang, Romina A. Romero, David L. Sultzer, Joshua D. Grill, Hye‐Won Shin
INTRODUCTIONAlzheimer's disease (AD) disproportionately affects minoritized populations who remain underrepresented in AD trials.METHODSWe partnered with local nursing community‐based organizations to implement a culturally tailored educational intervention and recruit Hispanic/Latino American, Filipino American, and Korean American adults aged 55 to 80 for the AHEAD study, a preclinical AD trial,
-
Blood‐derived microRNAs are related to cognitive domains in the general population Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-30 Konstantinos Melas, Valentina Talevi, Mohammed Aslam Imtiaz, Rika Etteldorf, Santiago Estrada, Dennis M. Krüger, Tonatiuh Pena‐Centeno, N. Ahmad Aziz, André Fischer, Monique M. B. Breteler
INTRODUCTIONBlood‐derived microRNAs (miRNAs) are potential candidates for detecting and preventing subclinical cognitive dysfunction. However, replication of previous findings and identification of novel miRNAs associated with cognitive domains, including their relation to brain structure and the pathways they regulate, are still lacking.METHODSWe examined blood‐derived miRNAs and miRNA co‐expression
-
Parallel electrophysiological abnormalities due to COVID‐19 infection and to Alzheimer's disease and related dementia Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-29 Yang Jiang, Jennifer Neal, Pradoldej Sompol, Görsev Yener, Xianghong Arakaki, Christopher M. Norris, Francesca R. Farina, Agustin Ibanez, Susanna Lopez, Abdulhakim Al‐Ezzi, Voyko Kavcic, Bahar Güntekin, Claudio Babiloni, Mihály Hajós
Many coronavirus disease 2019 (COVID‐19) positive individuals exhibit abnormal electroencephalographic (EEG) activity reflecting “brain fog” and mild cognitive impairments even months after the acute phase of infection. Resting‐state EEG abnormalities include EEG slowing (reduced alpha rhythm; increased slow waves) and epileptiform activity. An expert panel conducted a systematic review to present
-
-
Alzheimer's disease CSF biomarkers correlate with early pathology and alterations in neuronal and glial gene expression Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-28 Ali S. Ropri, Tiffany G. Lam, Vrinda Kalia, Heather M. Buchanan, Anne Marie W. Bartosch, Elliot H. H. Youth, Harrison Xiao, Sophie K. Ross, Anu Jain, Jayanta K. Chakrabarty, Min Suk Kang, Deborah Boyett, Eleonora F. Spinazzi, Gail Iodice, Robert A. McGovern, Lawrence S. Honig, Lewis M. Brown, Gary W. Miller, Guy M. McKhann, Andrew F. Teich
INTRODUCTIONNormal pressure hydrocephalus (NPH) patients undergoing cortical shunting frequently show early Alzheimer's disease (AD) pathology on cortical biopsy, which is predictive of progression to clinical AD. The objective of this study was to use samples from this cohort to identify cerebrospinal fluid (CSF) biomarkers for AD‐related central nervous system (CNS) pathophysiologic changes using
-
The moderating role of information processing speed in the relationship between brain remodeling and episodic memory in amnestic mild cognitive impairment Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-28 Jie Ma, Juan‐Juan Lu, Jia‐Jia Wu, Yun‐Ting Xiang, Mou‐Xiong Zheng, Xu‐Yun Hua, Jian‐Guang Xu
INTRODUCTIONThe role of information processing speed (IPS) on relationships between episodic memory (EM) and central remodeling features in amnestic mild cognitive impairment (aMCI) was investigated.METHODSNeuropsychological evaluations and multimodal magnetic resonance imaging were performed on 48 patients diagnosed with aMCI and 50 healthy controls (HC). Moderation models explored the moderating
-
Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF‐AD study Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-28 Rebecca G. Smith, Ehsan Pishva, Morteza Kouhsar, Jennifer Imm, Valerija Dobricic, Peter Johannsen, Michael Wittig, Andre Franke, Rik Vandenberghe, Jolien Schaeverbeke, Yvonne Freund‐Levi, Lutz Frölich, Philip Scheltens, Charlotte E. Teunissen, Giovanni Frisoni, Olivier Blin, Jill C. Richardson, Régis Bordet, Sebastiaan Engelborghs, Ellen de Roeck, Pablo Martinez‐Lage, Miren Altuna, Mikel Tainta, Alberto
INTRODUCTIONWe investigated blood DNA methylation patterns associated with 15 well‐established cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) pathophysiology, neuroinflammation, and neurodegeneration.METHODSWe assessed DNA methylation in 885 blood samples from the European Medical Information Framework for Alzheimer's Disease (EMIF‐AD) study using the EPIC array.RESULTSWe identified
-
How fiber bundle alterations differ in presumed LATE and amnestic Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-28 Aurélie Lebrun, Yann Leprince, Julien Lagarde, Pauline Olivieri, Martin Moussion, Camille Noiray, Michel Bottlaender, Marie Sarazin
INTRODUCTIONTypical Alzheimer's disease (AD) and limbic‐predominant age‐related TAR DNA‐binding protein 43 (TDP‐43) encephalopathy (LATE) are two neurodegenerative diseases that present with a similar initial amnestic clinical phenotype but are associated with distinct proteinopathies.METHODSWe investigated white matter (WM) fiber bundle alterations, using fixel‐based analysis, a state‐of‐the‐art diffusion
-
Alzheimer's disease and its family history reduce the risk of non‐Hodgkin's lymphoma: A Mendelian randomization study Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-28 Zilong Wang, Binyang Song, Jinhua Wang, Xiaobo Wang, Bo Tang
We recently read Association between Alzheimer's disease and risk of cancer: A retrospective cohort study in Shanghai, China, and the results suggested that Alzheimer's disease (AD) significantly increases the risk of lymphoma.1 However, several previous studies have consistently shown an inverse correlation between AD and cancer.2-4 Currently, the association between AD and hematological diseases
-
Sharing health care wishes among older adults with cognitive impairment in primary care: Results from a randomized controlled trial Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-27 Jennifer L. Wolff, John G. Cagle, Valecia Hanna, Sydney M. Dy, Diane Echavarria, Erin R. Giovannetti, Cynthia M. Boyd, Martha Abshire Saylor, Naaz Hussain, Jenni S. Reiff, Danny Scerpella, Talan Zhang, Vishaldeep Kaur Sekhon, David L. Roth
INTRODUCTIONBest practices for conducting advance care planning (ACP) among persons with cognitive impairment exist, but evidence‐based models are lacking for the primary care setting.METHODSWe tested a remote multicomponent ACP model (SHARE) versus minimally enhanced usual care in 273 person–family dyads from eight primary care practices.RESULTSMean patient age was 88.0 years, 85 (31.1%) were Black/Latino;
-
Correction to “Effect of gamification with a support partner to increase physical activity in older adults at risk for Alzheimer's disease: The STEP 4Life randomized clinical trial” Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-27
Greysen SR et al. Alzheimers Dement. 2024 Jul 4. https://doi.org/10.1002/alz.14058. In paragraph 3 of the “Statistical Analysis” section, the equation listed was incorrect. It should have read: Stepsij=β0+β1Baselinestepcountij+β2Arminterventionij+β3MonthJanuaryij+β4MonthFebruaryij+⋯+β13MonthNovemberij+bi+εij$$\begin{equation*}Step{{s}_{ij}}
-
Contribution of alpha-synuclein pathology to cerebral glucose metabolism in patients with amnestic MCI Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-23 Samir Abu-Rumeileh, Garegin Arajyan, Eric M. Reiman, Markus Otto, Christopher M. Weise
The in vivo detection of mixed Alzheimer's disease (AD) and α-synuclein (αSyn) pathology is important for clinical management and prognostic stratification. We investigated the contribution of αSyn pathology, detected by cerebrospinal fluid (CSF) seed amplification assay (αSyn SAA), on [18F]-fluorodeoxyglucose positron emission tomography (FDG PET) pattern in subjects with amnestic mild cognitive impairment
-
Long‐term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: An up to 10‐year follow‐up study Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-23 Hong Xu, Annegret Habich, Daniel Ferreira, Londos Elisabet, Eric Westman, Maria Eriksdotter
INTRODUCTIONWe aimed to assess the impact of cholinesterase inhibitors (ChEIs) and memantine on cognition, major adverse cardiovascular events (MACE) and mortality in dementia with Lewy bodies (DLB).METHODSA total of 1,095 incident DLB patients from the Swedish Registry on cognitive/dementia disorders were included. Using an inverse probability of treatment weighting, the effect of initiating ChEI
-
Distinct regional vulnerability to Aβ and iron accumulation in post mortem AD brains Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-23 Junye Yao, Zhenghao Li, Zihan Zhou, Aimin Bao, Zheng Wang, Hongjiang Wei, Hongjian He
INTRODUCTIONThe paramagnetic iron, diamagnetic amyloid beta (Aβ) plaques and their interaction are crucial in Alzheimer's disease (AD) pathogenesis, complicating non‐invasive magnetic resonance imaging for prodromal AD detection.METHODSWe used a state‐of‐the‐art sub‐voxel quantitative susceptibility mapping method to simultaneously measure Aβ and iron levels in post mortem human brains, validated by
-
Pan‐Canadian estimates of the prevalence and risks associated with critical wandering among home care clients Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-23 Antonio Miguel Cruz, Hector Perez, Micaela Jantzi, Lili Liu, John P. Hirdes
INTRODUCTIONWe used clinical assessment records to provide pan‐Canadian estimates of the prevalence and risks associated with recent (within the last 3 days) critical wandering among home care clients, with and without dementia.METHODSThe data source is interRAI Home Care (interRAI HC) assessments. The population was all long‐stay home care clients assessed between 2004 and 2021 in seven Canadian provinces
-
The relationship between adult hippocampal neurogenesis and cognitive impairment in Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-22 Joris N. Geigenmüller, Atefe R. Tari, Ulrik Wisloff, Tara L. Walker
Neurogenesis persists throughout adulthood in the hippocampus and contributes to specific cognitive functions. In Alzheimer's disease (AD), the hippocampus is affected by pathology and functional impairment early in the disease. Human AD patients have reduced adult hippocampal neurogenesis (AHN) levels compared to age‐matched healthy controls. Similarly, rodent AD models show a decrease in AHN before
-
Disrupted mitochondrial response to nutrients is a presymptomatic event in the cortex of the APPSAA knock‐in mouse model of Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-22 Andrés Norambuena, Vijay Kumar Sagar, Zhuoying Wang, Prakash Raut, Ziang Feng, Horst Wallrabe, Evelyn Pardo, Taylor Kim, Shagufta Rehman Alam, Song Hu, Ammasi Periasamy, George S. Bloom
INTRODUCTIONReduced brain energy metabolism, mammalian target of rapamycin (mTOR) dysregulation, and extracellular amyloid beta (Aβ) oligomer (xcAβO) buildup are some well‐known Alzheimer's disease (AD) features; how they promote neurodegeneration is poorly understood. We previously reported that xcAβOs inhibit nutrient‐induced mitochondrial activity (NiMA) in cultured neurons. We now report NiMA disruption
-
Association of polygenic risk scores with Alzheimer's disease and plasma biomarkers among Chinese older adults: A community‐based study Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-22 Tingting Hou, Keke Liu, Wenxin Fa, Cuicui Liu, Min Zhu, Xiaoyan Liang, Yifei Ren, Shan Xu, Xiang Wang, Shi Tang, Yongxiang Wang, Lin Cong, Qihuan Tan, Yifeng Du, Chengxuan Qiu
INTRODUCTIONWe examined the associations of polygenic risk score (PRS) with Alzheimer's disease (AD) and plasma biomarkers in the Chinese population.METHODSThis population‐based study used baseline data from MIND‐China (2018; n = 4873) and follow‐up data from dementia‐free individuals (2014–2018; n = 2117). We measured AD‐related plasma biomarkers in a subsample (n = 1256). Data were analyzed using
-
CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-22 Britney N. Lizama, Claire Williams, Hilary A. North, Kiran Pandey, Duc Duong, Valentina Di Caro, Adam P. Mecca, Kaj Blennow, Henrik Zetterberg, Allan I. Levey, Michael Grundman, Christopher H. van Dyck, Anthony O. Caggiano, Nicholas T. Seyfried, Mary E. Hamby
INTRODUCTIONCT1812 is in clinical development for the treatment of Alzheimer's disease (AD). Cerebrospinal fluid (CSF) exploratory proteomics was employed to identify pharmacodynamic biomarkers of CT1812 in mild to moderate AD from two independent clinical trials.METHODSUnbiased analysis of tandem‐mass tag mass spectrometry (TMT‐MS) quantitative proteomics, pathway analysis and correlation analyses
-
“Make research more people‐centered”: Two ADNI participants share recommendations for more inclusive Alzheimer's disease research Alzheimers Dement. (IF 13.0) Pub Date : 2024-08-22 Sarah Walter, Rochelle Long, Cynthia Huling Hummel
We want to congratulate and thank the thousands of people who have given of their time and energy to gather and formulate the necessary data to study Alzheimer's disease. Over the past 20 years, more than 2400 participants have taken part in Alzheimer's Disease Neuroimaging Initiative (ADNI) at one of the many sites across North America. So much has been learned because of our willingness to step up